LONGTERM, MULTICENTER, MULTINATIONAL DATA IN PULMONARY ARTERIAL HYPERTENSION PRESENTED AT ISHLT MEETING
NICE, FR April, 18, 2015 – Today at the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions , researchers presented long-term results from The GRIPHON trial demonstrating that selexipag (Uptravi®) is an effective treatment therapy for pulmonary arterial hypertension (PAH). The trial, a multicenter,